Lilly Q1 ’17 Earnings Update
Lilly hosted its Q1 ’17 earnings call and provided an update to its diabetes portfolio including pipeline and LCM activities.
This content is for Read Less members only.
Already a member? Log in here
Category Archives: SGLT2i
Lilly Initiates Ph1 for New OAD
A Lilly sponsored Ph1 ClinicaTrials.gov record has been observed for LY3325656. According to the record, the compound is dosed orally and is being compared to liraglutide and in combination with sitagliptin. MOA for LY3325656 remains to be determined.
This content is for Read Less members only.
Already a member? Log in here
J&J Q1 ’17 Earnings Update
J&J presented its Q1 ’17 earnings results and provided a brief update to its diabetes business including drugs and devices. Of note, J&J is hosting its Pharmaceutical Business Review on May 17.
This content is for Read Less members only.
Already a member? Log in here
Invokana CKD Outcomes Trial (CREDENCE) Primary Completion Date Delayed
The ClincalTrials.gov record for the CREDENCE trial has been updated to reflect a later primary completion date. The estimated primary completion date has been pushed back from February 11, 2019 to June 28, 2019, which may be due to trial recruitment.
This content is for Read Less members only.
Already a member? Log in here
Lilly Increases Diabetes Manufacturing Investment in 2017
Lilly has announced intentions to invest $850M in its US operations in 2017 including $85M to expand the Trulicity device assembly operations. Additionally, Lilly announced the dedication of a $140M insulin cartridge facility.
This content is for Read Less members only.
Already a member? Log in here
Lilly Partners with Sansum for Diabetes Research in the Latino Population
Lilly and the William Sansum Diabetes Center in Santa Barbara, California have entered into a research collaboration to further understand the unmet needs related to diabetes in the Latino population.
This content is for Read Less members only.
Already a member? Log in here
Lexicon Q4 ’16 Earnings Update
Lexicon hosted its Q4 and full-year 2016 earnings call and provided an update to its diabetes pipeline.
This content is for Read Less members only.
Already a member? Log in here
Merck/Pfizer Filed Ertugliflozin and FDCs in December 2016
Merck/Pfizer quietly filed their SGLT2i, ertugliflozin, FDC with metformin, and FDC with Januvia (sitagliptin) in December 2016.
This content is for Read Less members only.
Already a member? Log in here
Lexicon Presentation at Leerink Healthcare Conference
Lexicon recently presented at the Leerink Global Healthcare Conference and provided updates to its diabetes development programs.
This content is for Read Less members only.
Already a member? Log in here
J&J’s Invokana Receives Toe Amputation Warning from EMA
EMA has issued a warning that Invokana is associated with increased cases of lower limb amputations, particularly toes, in the CANVAS and CANVAS-R studies. The underlying cause remains unknown. While EMA has concluded the risk exists, the issue remains under investigation with FDA.
This content is for Read Less members only.
Already a member? Log in here